To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
Status:
Completed
Trial end date:
2019-03-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetics, as well as to evaluate the
safety, tolerability and immunogenicity of HD204, US-Avastin and EU-Avastin in healthy male
subjects after intravenous administration of a single dose..